Long-Term Adherence to Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis
Carina M E Hansen1,2, Badr Zendaky3, Annelies M Zwitserloot4
1Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen (UMCG), Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. c.m.e.hansen@umcg.nl.
Introduction:
Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are the cornerstone treatment for CF, but nonadherence can reduce their effect. Long-term adherence data on elexacaftor/tezacaftor/ivacaftor (ETI) combined with the evening dose ivacaftor (IVA) are lacking. The aim of this study was to determine 3-year adherence to ETI and IVA based on pharmacy refill data.
Methods:
A retrospective observational cohort study was conducted using pharmacy refill data. Medication adherence was calculated using the proportion of days covered (PDC). The primary outcome was the PDC for ETI and IVA, which were calculated at 1, 2, and 3 years after initiating ETI and IVA. The secondary outcome was the proportion of non-adherent people with CF (pwCF), defined as having a PDC < 0.8.
Results:
A total of 128 pwCF were included (75 male [59%], mean age 28.8 ± 15.5 years). At year 1, the PDCs for ETI and IVA (N = 128 and 112) were (median, range) 0.98 (0.69-1.0) and 0.98 (0.68-1.0); at 2 years (N = 105 and 95), 0.99 (0.54-1.0) and 1.0 (0.69-1.0), and at 3 years (N = 56 and 51), 0.98 (0.49-1.0) and 0.99 (0.54-1.0). Over time, a statistically significant decrease in PDC was observed [p = 0.01 (ETI, years 1 vs. 3) and p = < 0.01 (IVA)]. The percentage of non-adherent pwCF increased over time, from 3.6% (IVA) and 3.3% (ETI) at year 1 to 15.7% (IVA) and 12.5% (ETI) at year 3.
Conclusions:
Three-year adherence to ETI and IVA based on pharmacy refill data was high, yet declined over time.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Drugs for Treatment of Ulcerative Colitis in IBD
